Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba(R) (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries

SAN DIEGO, May 2, 2017 -- (Healthcare Sales & Marketing Network) -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Navamedic AB, an affiliate of Navamedic ASA (Oslo:NAVA... Biopharmaceuticals, Distribution Orexigen Therapeutics, Navamedic AB, Mysimba, naltrexone, bupropion
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news